Independent Advisor Alliance Acquires Shares of 89,475 ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Independent Advisor Alliance acquired a new stake in ADMA Biologics, purchasing 89,475 shares valued at approximately $1.775 million during the first quarter.
• ADMA Biologics reported earnings of $0.15 per share, exceeding expectations, with quarterly revenue of $121.98 million, representing a 13.8% year-over-year increase.
• Several institutional investors increased their positions in ADMA, with hedge funds collectively owning 75.68% of the company's stock, reflecting strong investor interest.

Independent Advisor Alliance bought a new position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 89,475 shares of the biotechnology company's stock, valued at approximately $1,775,000.

A number of other institutional investors have also bought and sold shares of the business. Cetera Investment Advisers grew its stake in shares of ADMA Biologics by 1.3% in the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock worth $1,002,000 after acquiring an additional 670 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ADMA Biologics by 1.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock worth $1,323,000 after acquiring an additional 711 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in shares of ADMA Biologics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock worth $404,000 after acquiring an additional 746 shares in the last quarter. GF Fund Management CO. LTD. grew its stake in shares of ADMA Biologics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company's stock worth $120,000 after acquiring an additional 1,089 shares in the last quarter. Finally, Journey Strategic Wealth LLC grew its stake in shares of ADMA Biologics by 6.6% in the first quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company's stock worth $354,000 after acquiring an additional 1,102 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 0.1%

Shares of ADMA stock traded up $0.02 on Friday, reaching $16.99. 3,108,545 shares of the stock were exchanged, compared to its average volume of 3,534,720. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The business's 50 day moving average price is $18.29 and its 200 day moving average price is $18.85. The company has a market capitalization of $4.05 billion, a price-to-earnings ratio of 19.76 and a beta of 0.38. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. The firm had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company's revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.13 earnings per share. As a group, sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares in the company, valued at $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director owned 478,194 shares of the company's stock, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 464,621 shares of company stock worth $9,644,269. Corporate insiders own 3.50% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on ADMA shares. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial boosted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.